You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 25, 2024

Claims for Patent: 5,763,407


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,763,407
Title: High-purity desmopressin produced in large single batches
Abstract:A process for the manufacture of high purity desmopressin produced in single batches of substantial size and a method of treating diabetes insipidus with the high purity desmopressin produced therefrom.
Inventor(s): Larsson; Krister (Malmo, SE), Mellbrand; Thomas (Malmo, SE), Mornstam; Birgitta (Bunkeflostrand, SE), Roschester; Jan (Lund, SE), Skoldback; Jan-Ake (Malmo, SE)
Assignee: Ferring BV (Hoofddorp, NL)
Application Number:08/797,826
Patent Claims: 1. A method for treating diabetes insipidus, hemophilia A and von Willebrand's disease, comprising oral, nasal or intravenous administration of a dose of desmopressin effective to produce a physiological effect, said desmopressin produced in a single batch having a weight of at least about 50 g containing at least 98.5% by weight of desmopressin (C.sub.46 H.sub.64 N.sub.14 O.sub.12 S.sub.2) in respect of adjoining matter other than water and acetic acid, said batch produced with a final synthetic step in which at least about 1 kg of mercapto-propionyl-Tyr-Phe-Gln-Asn-Cys-Pro-D-Arg-Gly-NH.sub.2 (SEQ ID NO: 2) or a derivative thereof, said derivative being stable at neutral or slightly acidic conditions, is dissolved in a protic solvent at neutral or slightly acidic conditions to form a reactant solution into which a second solution of iodine in a protic solvent or solvent mixture is introduced under agitation to form a reactant/reagent solution in which desmopressin is being formed.

2. A single oral dose of desmopressin effective to produce a physiological effect for treatment of diabetes insipidus, hemophilia A and von Willebrand's disease, said dose prepared from a desmopressin batch produced in single batches of desmopressin having a weight of at least about 500 g containing at least 98.5% by weight of desmopressin (C.sub.46 H.sub.64 N.sub.14 O.sub.12 S.sub.2) in respect of adjoining matter other than water and acetic acid, said batches produced with a final synthetic step, in which at least about 1 kg of mercapto-propionyl-Tyr-Phe-Gln-Asn-Cys-Pro-D-Arg-Gly-NH.sub.2 (SEQ ID NO: 2) or a derivative thereof, said derivative being stable at neutral or slightly acidic conditions, is dissolved in a protic solvent at neutral or slightly acidic conditions to form a reactant solution into which a second solution of iodine in a protic solvent or solvent mixture is introduced under agitation to form a reactant/reagent solution in which desmopressin is being formed.

3. A single oral dose of desmopressin effective to produce a physiological effect for treatment of diabetes insipidus, hemophilia A and von Willebrand's disease, said dose prepared from a single batch of desmopressin containing no less than 44 g of desmopressin (C.sub.46 (H.sub.64 N.sub.14 O.sub.12 S.sub.2) and no more than a total of 1.5% by weight of adjoining matter with respect to desmopressin (C.sub.46 H.sub.64 N.sub.14 O.sub.12 S.sub.2) other than water and acetic acid.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.